Infectious Diseases

Several viruses such as Kaposi’s sarcoma herpes virus, the Epstein-Barr virus, as well as hepatitis C and B viruses have been recognized as oncogenic. The replication of these viruses is dependent on uninterrupted signaling through the Ras/Raf/MEK/MAPK signal transduction pathway.

The validation of NexusPharma's Ras-Raf interaction inhibitors as effective anti-oncogenic agents may be expected to have a significant impact in the treatment of many chronic, widely distributed, and debilitating viruses that currently lack effective treatments and pose significant public health burdens. First results demonstrated the ability of NexusPharma's compounds to inhibit anchorage-independent growth and proliferation of cells transformed with viral oncoproteines.
Home | Contacts | Directions